Recent developments include FDA clearance for a Phase 2 clinical study of Vilamakitug in axial spondyloarthritis and the appointment of a renowned scientist to the Board of Directors, reflecting progress in clinical and governance areas.

• XBiotech was granted FDA clearance for a Phase 2 study of Vilamakitug in axial spondyloarthritis as of June 16, 2026 [N1].
• The company appointed a renowned scientist to its Board of Directors as of March 14, 2026 [N2].

XBiotech's recent FDA clearance for a Phase 2 study of Vilamakitug in axial spondyloarthritis demonstrates regulatory progress and potential clinical validation of its therapeutic approach. The appointment of a renowned scientist to the Board may enhance scientific leadership and strategic direction. The company's strong liquidity position provides financial flexibility to support ongoing research and development activities. The experienced management and board team contribute to robust governance and operational oversight.

As a clinical-stage biopharmaceutical company, XBiotech faces inherent risks including the uncertainty of clinical trial outcomes and regulatory approvals. The company reported a net loss for the recent quarter, reflecting ongoing investment in development without current product revenue. Leadership transitions, such as the recent appointment of an interim CEO, may introduce operational challenges. The company’s financial sustainability depends on continued access to capital and successful advancement of its clinical programs.

XBiotech's moat is primarily based on its proprietary antibody technology platform and its clinical-stage pipeline, including Vilamakitug. The company's founder and leadership bring extensive scientific expertise and intellectual property, supported by a board with strong governance and risk oversight. The FDA clearance for Phase 2 clinical trials indicates regulatory progress, which is a critical barrier in biopharmaceutical development. However, as a clinical-stage company, it faces typical industry risks including clinical trial outcomes, regulatory approvals, and capital requirements.

• Clinical Development Risk: The success of XBiotech depends on the outcomes of clinical trials, including the ongoing Phase 2 study of Vilamakitug. Negative or inconclusive results could materially affect the company’s prospects.
• Regulatory Risk: Obtaining and maintaining regulatory approvals is critical. Delays or failures in regulatory processes could impact the company’s ability to commercialize its therapies.
• Financial Risk: XBiotech reported net losses and relies on its cash reserves and potential financing to fund operations. Insufficient capital could limit its ability to continue development activities.
• Leadership and Governance Risk: Recent leadership changes, including the appointment of an interim CEO, may affect strategic execution and operational continuity.

• XBiotech Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies.
• The company is incorporated in British Columbia, Canada, with principal executive offices in Austin, Texas, USA.
• XBiotech's common stock trades on the NASDAQ Global Select Market under the ticker XBIT.
• As of June 30, 2026, XBiotech reported cash and cash equivalents of $109.5 million and current assets of $111.2 million, with current liabilities of $3.35 million, resulting in a current ratio of 33.15 and a cash ratio of 32.67, indicating strong liquidity.
• For the quarter ended June 30, 2026, the company reported a net loss of $6.7 million and basic earnings per share of -$0.22.
• The company had 30,487,731 shares outstanding as of March 13, 2026.
• John Simard is the founder and Chairman of the Board; he served as CEO until December 8, 2025, and continues as Chairman and Scientific Advisor.
• Dr. Sushma Shivaswamy was appointed Interim CEO in December 2026 and continues as Chief Scientific Officer, overseeing R&D and manufacturing operations.
• The Board of Directors includes experienced members with backgrounds in medicine, finance, policy, and science, including Dr. Thomas Kündig, Craig Rademaker, Dr. Tevi Troy, and Dr. David Soffer.
• The Board oversees risk management directly and through committees: Audit, Compensation, and Nominating and Corporate Governance.
• XBiotech was granted FDA clearance for a Phase 2 clinical study of Vilamakitug in axial spondyloarthritis as of June 16, 2026.
• The company appointed a renowned scientist to its Board of Directors as of March 14, 2026.
• The company filed an amended 10-K on April 29, 2026, and a 10-Q on August 13, 2026, providing updated financial and governance disclosures.